obesity drug glp-1 news today october 2025 GLP-1 trends 2025: real-world data, patient outcomes & future therapies New weight-loss drugs surge in

Referral to specialist hepatology services may be appropriate for patients with advanced liver disease or diagnostic uncertainty

Products claiming to prevent or treat disease, or to restore, correct or modify physiological functions, may be considered medicinal products requiring proper licensing

Its easy to feel lost sorting through weight loss medications, especially when the internet is packed with opinions

For a deeper look at using health spending funds, see our guide to HSA and FSA coverage for semaglutide and tirzepatide programs

The RAND Education and Labor division is dedicated to improving education and expanding economic opportunities for all through research and analysis